Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes (NCT07284979)
A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
Who can join: Review the eligibility criteria below.
Location: Kailera Clinical Site — Glendale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (53 Sites)
Showing the first 25 of 53 sites.
- Kailera Clinical Site — Glendale, Arizona
- Kailera Clinical Site — Phoenix, Arizona
- Kailera Clinical Site — Little Rock, Arkansas
- Kailera Clinical Site — Northridge, California
- Kailera Clinical Site — Oceanside, California
- Kailera Clinical Site — Hamden, Connecticut
- Kailera Clinical Site — Stamford, Connecticut
- Kailera Clinical Site — Orange City, Florida
- Kailera Clinical Site — Albany, Georgia
- Kailera Clinical Site — Chicago, Illinois
- Kailera Clinical Site — Skokie, Illinois
- Kailera Clinical Site — Newton, Kansas
- Kailera Clinical Site — Shreveport, Louisiana
- Kailera Clinical Site — Farmington Hills, Michigan
- Kailera Clinical Site — Missoula, Montana
- Kailera Clinical Site — Las Vegas, Nevada
- Kailera Clinical Site — Albany, New York
- Kailera Clinical Site — Morehead City, North Carolina
- Kailera Clinical Site — Morrisville, North Carolina
- Kailera Clinical Site — Norman, Oklahoma
- Kailera Clinical Site — East Greenwich, Rhode Island
- Kailera Clinical Site — North Charleston, South Carolina
- Kailera Clinical Site — Spartanburg, South Carolina
- Kailera Clinical Site — Brownsville, Texas
- Kailera Clinical Site — San Antonio, Texas
📞 Contact the Study Coordinator
Phone: (781) 317-0291
Email: info-clinicalstudies@kailera.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Obesity
- Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools — Tampa, Florida
- SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity — Tucson, Arizona
- Piloting a Patient Navigator Program for Weight Loss — Philadelphia, Pennsylvania
- Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) — Mesa, Arizona
- Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects — Orlando, Florida
- Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans — Pittsburgh, Pennsylvania
Explore by condition: All Obesity clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.